Navigation Links
Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference

THOUSAND OAKS, Calif., Nov. 20, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 24th Annual Piper Jaffray Healthcare Conference on Wednesday, Nov. 28, 2012, at the New York Palace hotel in New York City, beginning at 11:30 a.m. Eastern Standard Time.  Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website,, under Investors.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit  Follow us on

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Eric Hyllengren, 805-447-1060 (investors)


Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
2. Amgen Announces 2012 Third Quarter Dividend
3. Amgen to Present at the Leerink Swann Global Healthcare Conference
4. Amgen to Acquire Micromet
5. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
6. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
7. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
8. Amgen Announces 2012 First Quarter Dividend
9. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
10. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
11. MiMedx Group to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
Post Your Comments:
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
Breaking Biology Technology:
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):